A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%

NCT01437982 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Conjunctivitis, Seasonal Allergic
Conjunctivitis, Giant Papillary
Inflammation

Interventions

DRUG: Loteprednol Etabonate
DRUG: Prednisolone Acetate 1% Oph Susp

Sponsor

Bausch & Lomb Incorporated